Transition Therapeutics Inc. (TTH.TO)
-Toronto 3.19 
0.09(2.90%) 3:28PM EDT
| Prev Close: | 3.10 |
|---|
| Open: | 3.10 |
|---|
| Bid: | 3.15 |
|---|
| Ask: | 3.18 |
|---|
| 1y Target Est: | 3.25 |
|---|
| Beta: | 0.66 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.05 - 3.19 |
|---|
| 52wk Range: | 1.74 - 3.72 |
|---|
| Volume: | 11,199 |
|---|
| Avg Vol (3m): | 4,379 |
|---|
| Market Cap: | 85.62M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | 0.06 (0.20%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Transition Therapeutics Announces Third Quarter Fiscal 2013 Financial ResultsCNW Group(Tue, May 7)
- Transition Therapeutics Announces Third Quarter Fiscal 2013 Financial ResultsPR Newswire(Tue, May 7)
- Q3 2013 TRANSITION THERAPEUTICS INC Earnings Release - After Market CloseCCBN(Tue, May 7)
- Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2013 Financial Results on Tuesday, May 7th, at 4:30 P.M. ESTCNW Group(Mon, May 6)
- Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2013 Financial Results on Tuesday, May 7th, at 4:30 P.M. ESTPR Newswire(Mon, May 6)
- Transition Therapeutics Still Undervalued: Good Trial Outcome Shifts Focus To Lilly Decisionat Seeking Alpha(Tue, Apr 30)
- Transition Therapeutics Announces Results of Clinical Study of Type 2 Diabetes Drug Candidate TT-401CNW Group(Tue, Apr 30)
- Transition Therapeutics Announces Results of Clinical Study of Type 2 Diabetes Drug Candidate TT-401PR Newswire(Tue, Apr 30)
- Transition Therapeutics Announces Second Quarter Fiscal 2013 Financial ResultsCNW Group(Thu, Feb 7)
- Transition Therapeutics Announces Second Quarter Fiscal 2013 Financial ResultsPR Newswire(Thu, Feb 7)
- Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2013 Financial Results on Thursday, February 7th, at 4:30 P.M. ESTCNW Group(Mon, Feb 4)
- Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2013 Financial Results on Thursday, February 7th, at 4:30 P.M. ESTPR Newswire(Mon, Feb 4)
- Transition Therapeutics To Trade Higher Into Upcoming Trial Results For Diabetes Drugat Seeking Alpha(Mon, Jan 28)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 7.69 |
|---|
| Ex-Dividend Date: | 29-Dec-10 |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.04 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.11 |
|---|
| Mean Recommendation*: | 2.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Transition Therapeutics Inc., a biopharmaceutical company, engages in developing therapeutics for various disease indications primarily in Canada. Its product candidates include ELND005 (AZD-103), a Phase II clinical trial product for the treatmen...
View More